TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31056252

Group type: EXPERIMENTAL
Intervention: Everolimus-based immunosuppression (EVR) with reduced cyclosporin A
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard immunosuppression (STD) with standard cyclosporin A and mycophenolate mofetil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Everolimus-based immunosuppression (EVR) with MFI cut-off level set to 6000
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard immunosuppression (STD) with MFI cut-off level set to 6000
Number of subjects: 24
Study: 27822663

Group type: EXPERIMENTAL
Intervention: Coping Cat program (CBT-based intervention)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 141
Study: 27180314

Group type: EXPERIMENTAL
Intervention: Ibogaine 20 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Paroxetine or placebo (control)
Number of subjects: 21
Study: 24401051

Group type: EXPERIMENTAL
Intervention: Upper-airway stimulation
Number of subjects: 126
Study: 22429766

Group type: EXPERIMENTAL
Intervention: Recent regular aspirin use
Number of subjects: 4771

Group type: EXPERIMENTAL
Intervention: Recent regular ibuprofen use
Number of subjects: 4771

Group type: EXPERIMENTAL
Intervention: Frequency of NSAID use
Number of subjects: 4771

Group type: EXPERIMENTAL
Intervention: Any recent NSAID use
Number of subjects: 4771
Study: 19769500

Group type: EXPERIMENTAL
Intervention: Autograft bone harvested from the iliac crest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allograft bone from either cadaveric iliac crest or fibula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Titanium cages and rectangular fusion devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyetheretherketone cages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenic protein-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 0
Study: 17126403

Group type: EXPERIMENTAL
Intervention: Dorzolamide treatment
Number of subjects: 854

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 854
Study: 15896581

Group type: EXPERIMENTAL
Intervention: PCEA with 0.1% bupivacaine (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PCEA without 0.1% bupivacaine (Group 1)
Number of subjects: 30
Study: 15669935

Group type: EXPERIMENTAL
Intervention: Storytelling and conversations (Group B)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dance, rhythm, and songs (Group A)
Number of subjects: 6
Study: 10546604

Group type: EXPERIMENTAL
Intervention: Vastus splitting approach
Number of subjects: 51

Group type: COMPARATOR
Intervention: Median parapatellar approach
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 51
Study: 9076841

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg day-1
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg day-1
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Policosanol 40 mg day-1
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 1859490

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg weekly, increased based on clinical improvement
Number of subjects: 64

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 100 mg daily, increased based on clinical improvement
Number of subjects: 64
Study: 6356900

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 91
Study: 31705307

Group type: EXPERIMENTAL
Intervention: casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) slurry
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PAA‐ACP@aMSN slurry
Number of subjects: 36

Group type: COMPARATOR
Intervention: artificial saliva solution (negative control)
Number of subjects: 36
Study: 30689016

Group type: EXPERIMENTAL
Intervention: Equivocal participants
Number of subjects: 65
Study: 29352829

Group type: EXPERIMENTAL
Intervention: Multiple-micronutrient powder (daily dose for 3 months)
Number of subjects: 722

Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 722
Study: 27148807

Group type: EXPERIMENTAL
Intervention: SAPT with PLGM activated
Number of subjects: 36

Group type: COMPARATOR
Intervention: SAPT alone
Number of subjects: 36
Study: 24673045

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 160

Group type: COMPARATOR
Intervention: Far-infrared therapy
Number of subjects: 160
Study: 22287748

Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Classical radical hysterectomy (RH)
Number of subjects: 56
Study: 20185426

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 810
Study: 17983507

Group type: COMPARATOR
Intervention: Group O (Oxytocin): 20 U oxytocin injected into the uterine plus 20 U oxytocin intravascularly, 152 women
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Group O + H (Oxytocin + Hemabat): 20 U oxytocin and 250 microg hemabat injected into the uterine, 192 women
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Group H (Hemabat): 250 microg hemabat injected into the uterine, 125 women
Number of subjects: 457
Study: 16257846

Group type: EXPERIMENTAL
Intervention: Haemodialysis patients
Number of subjects: 11
Study: 12161488

Group type: EXPERIMENTAL
Intervention: One etonogestrel implant
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Two etonogestrel implants
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (baseline testosterone treatment)
Number of subjects: 28
Study: 10198397

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF, 300 microgram sc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7762524

Group type: EXPERIMENTAL
Intervention: Rectal acetate (12.5 mmol [1,2‐13C]sodium acetate)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous acetate (12.5 mmol [1,2‐13C]sodium acetate)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Rectal acetate with propionate (6 mmol sodium propionate)
Number of subjects: 5
Study: 30559087

Group type: EXPERIMENTAL
Intervention: Educational tools (informative pamphlet, video, pictographic magnet)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Educational tools (pamphlet)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Educational tools (video)
Number of subjects: 269
Study: 29370008

Group type: EXPERIMENTAL
Intervention: Nutritional support initiated < 48 hours after injury
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nutritional support initiated 48 to < 72 hours after injury
Number of subjects: 90

Group type: COMPARATOR
Intervention: No nutritional support over first 7 days
Number of subjects: 90
Study: 28007026

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorouracil plus cisplatin
Number of subjects: 0
Study: 24846822

Group type: EXPERIMENTAL
Intervention: Hydromorphone ER (8-32 mg)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Oxycodone CR (10-40 mg)
Number of subjects: 260
Study: 22385928

Group type: EXPERIMENTAL
Intervention: Experimental dentifrice (2% strontium chloride and 5% potassium nitrate)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control dentifrice (no active ingredients)
Number of subjects: 81
Study: 18931525

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) treatment for 10 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Meta-analysis of hydrocortisone treatment
Number of subjects: 46
Study: 17535145

Group type: EXPERIMENTAL
Intervention: Sitting training protocol (2-week duration, involving reaching tasks beyond arm's length)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham sitting training protocol (2-week duration, involving cognitive-manipulative tasks within arm's length)
Number of subjects: 12
Study: 15074436

Group type: EXPERIMENTAL
Intervention: 6-month exercise training program (Group A: 16 patients)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (Group B: 10 patients)
Number of subjects: 26
Study: 16134519

Group type: EXPERIMENTAL
Intervention: Transamin 1.0 g i.v.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Transamin 0.5 g i.v.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: aminomethylbenzoic acid 0.5 g i.v.
Number of subjects: 400

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 400
Study: 9972173

Group type: EXPERIMENTAL
Intervention: Test toothpaste with zinc citrate trihydrate (ZCT) and triclosan in microgranules, delivered in a silica-based toothpaste containing 1450 ppm F as sodium fluoride, used for 13 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control fluoridated toothpaste with no anti-calculus active, used for 13 weeks.
Number of subjects: 0
Study: 8048854

Group type: EXPERIMENTAL
Intervention: Intrathoracic stomach after subtotal esophagectomy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Histamine blocker treatment for hemorrhagic ulcers
Number of subjects: 21
Study: 3393383

Group type: EXPERIMENTAL
Intervention: Piperacillin 600 mg/kg/day (P)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Piperacillin 600 mg/kg/day plus tobramycin (PT)
Number of subjects: 17
Study: 30439725

Group type: EXPERIMENTAL
Intervention: Exercise targeting segmental motion in mid‐thoracic spine for 2 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine athletic training
Number of subjects: 20
Study: 31758194

Group type: EXPERIMENTAL
Intervention: DHA quartile Q4
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: DHA quartile Q2
Number of subjects: 405
Study: 29511965

Group type: EXPERIMENTAL
Intervention: Weight-loss intervention (LEAN trial)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Baseline BMI correlation (HOPE trial)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ingenuity Pathway Analysis (IPA)
Number of subjects: 121
Study: 28317138

Group type: EXPERIMENTAL
Intervention: Psychiatry specialty pharmacist intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (hospital pharmacist intervention)
Number of subjects: 25
Study: 25046536

Group type: EXPERIMENTAL
Intervention: CSE/CHX - Clearfil SE Bond + CHX
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CSE - Clearfil SE Bond
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ADS/CHX - AdheSE + CHX
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ADS - AdheSE
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CSE and CSE/CHX)
Number of subjects: 22
Study: 23079690

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg delayed-release (DR) weekly (FB)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg delayed-release (DR) weekly (BB)
Number of subjects: 922

Group type: COMPARATOR
Intervention: Risedronate 5 mg immediate-release (IR) daily
Number of subjects: 922
Study: 21570934

Group type: EXPERIMENTAL
Intervention: Biological causal model
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Psychological causal model
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Combined causal model (biological and psychological)
Number of subjects: 461

Group type: COMPARATOR
Intervention: No causal explanation
Number of subjects: 461
Study: 18490891

Group type: EXPERIMENTAL
Intervention: Brief group intervention combining stress management psycho-education and physical activity
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual-care (control)
Number of subjects: 87
Study: 16552618

Group type: EXPERIMENTAL
Intervention: Cannabis extract
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 630

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study: 14750508

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10790473

Group type: EXPERIMENTAL
Intervention: Cumulative duration of middle ear effusion (MEE) in the first year of life
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Cumulative duration of middle ear effusion (MEE) during antecedent periods
Number of subjects: 241

Group type: COMPARATOR
Intervention: Socioeconomic status
Number of subjects: 241
Study: 8804494

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1321509

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 30 mg subcutaneously every 12 h for up to 14 days
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 6392163

Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 50

Group type: COMPARATOR
Intervention: Renografin-76
Number of subjects: 50
Study: 31796805

Group type: EXPERIMENTAL
Intervention: 5-day transcranial direct current stimulation (tDCS) targeting the somatosensory representation of the whole body (S1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional Source Separation algorithm for brain activity measurement
Number of subjects: 0
Study: 28977360

Group type: EXPERIMENTAL
Intervention: Baseline 3MS score
Number of subjects: 5596

Group type: EXPERIMENTAL
Intervention: Change in 3MS as a time-varying covariate
Number of subjects: 5596
Study: 27509020

Group type: EXPERIMENTAL
Intervention: Celgosivir (400 mg loading dose and 200 mg bid over 5 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Celgosivir
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22551775

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied to the right prefrontal cortex at 10 Hz, 100% of the observed motor threshold, for 2000 pulses per session, in a 10-session course over 2 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 9
Study: 20685721

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional transcutaneous electrical nerve stimulation treatment
Number of subjects: 40
Study: 18595903

Group type: EXPERIMENTAL
Intervention: Neuromuscular training programme
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 457
Study: 15293416

Group type: EXPERIMENTAL
Intervention: Uno (Pulpdent)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prime&Bond NT (PBNT, Dentsply Caulk)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Single Bond (SB, 3M ESPE)
Number of subjects: 18
Study: 11506214

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Coordination training
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-training group
Number of subjects: 102
Study: 9686709

Group type: EXPERIMENTAL
Intervention: Patient-specific information on prognoses and specially trained nurse to facilitate decision making
Number of subjects: 14
Study: 7517256

Group type: EXPERIMENTAL
Intervention: Oral gammaglobulin (50 mg/kg daily in four divided doses for 28 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 2560521

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (estrone sulfate) at a dose of 1.25 mg/day for 6 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Untreated women with SDAT
Number of subjects: 7
Study: 918793

Group type: EXPERIMENTAL
Intervention: Non-rebreathing (semiclosed) circuit enflurane anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaporizer out of circle (VOC) rebreathing system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaporizer in circle (VIC) system
Number of subjects: 0
Study: 30355445

Group type: EXPERIMENTAL
Intervention: LSD (100 µg po)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketanserin + LSD
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 24
Study: 26780757

Group type: EXPERIMENTAL
Intervention: Bridging with low-molecular-weight heparin during interruption of vitamin K antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual peri-interventional management based on risk profile
Number of subjects: 0
Study: 24118931

Group type: EXPERIMENTAL
Intervention: Twice-daily premixed protamine-aspart/aspart insulin (PM-2)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Once-daily insulin glargine plus zero to one prandial insulin glulisine injection (G+1)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus zero to three prandial injections (G+3)
Number of subjects: 588
Study: 22420675

Group type: EXPERIMENTAL
Intervention: professionally facilitated peer group intervention for HIV prevention
Number of subjects: 400
Study: 19841158

Group type: EXPERIMENTAL
Intervention: Silymarin (140, 280, 560, or 700 mg every 8 hours for 7 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18289823

Group type: EXPERIMENTAL
Intervention: Anti-stigma printed materials (Reading Group, RG)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Anti-stigma computer program (Program Group, PG)
Number of subjects: 193

Group type: COMPARATOR
Intervention: No intervention (Control Group, CG)
Number of subjects: 193
Study: 16163900

Group type: EXPERIMENTAL
Intervention: Glucophage mite (Germany)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glucophage mite (France)
Number of subjects: 24
Study: 12913100

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (30 Gy IF + 10 Gy to bulky disease)
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Extended field radiotherapy (30 Gy EF + 10 Gy to bulky disease)
Number of subjects: 1204
Study: 11061613

Group type: EXPERIMENTAL
Intervention: CV6504, 100 mg TDS, orally for three months
Number of subjects: 31
Study: 8771625

Group type: EXPERIMENTAL
Intervention: Self-hypnosis training
Number of subjects: 35

Group type: COMPARATOR
Intervention: No explicit training in stress-reduction strategies (Control)
Number of subjects: 35
Study: 1617044

Group type: EXPERIMENTAL
Intervention: Cefprozil (500 mg twice daily)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cefaclor (500 mg three times daily)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cefuroxime axetil (500 mg twice daily)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500 mg/125 mg three times daily)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 3
Study: 6143188

Group type: EXPERIMENTAL
Intervention: Plasma exchange (5 exchanges in 10 days, 55 ml plasma/kg body weight/exchange)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal supportive care
Number of subjects: 30
Study: 31772092

Group type: EXPERIMENTAL
Intervention: Inspection from the Labour Inspection Authority
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidance through an online interactive risk-assessment tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidance on psychosocial, organisational and mechanical work environment through workshops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 29290066

Group type: EXPERIMENTAL
Intervention: Tanning behaviors (indoor tanning, concurrent tanning types)
Number of subjects: 818
Study: 27011355

Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 23

Group type: COMPARATOR
Intervention: Relaxation programme
Number of subjects: 23
Study: 24408116

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 23173253

Group type: EXPERIMENTAL
Intervention: Massage combined Chinese materia medica (CMM) footbath fumigation and washing
Number of subjects: 61

Group type: COMPARATOR
Intervention: Oral administration of meloxicam
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Massage combined CMM footbath fumigation and washing
Number of subjects: 61
Study: 20405136

Group type: EXPERIMENTAL
Intervention: Cow's milk formula
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Donor breast milk
Number of subjects: 6209

Group type: COMPARATOR
Intervention: Control subjects (non-IgE-mediated cow's milk allergy)
Number of subjects: 6209
Study: 17922170

Group type: EXPERIMENTAL
Intervention: Searching tutorial (up to 6 1-hour small group sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no tutorial)
Number of subjects: 0
Study: 16034238

Group type: EXPERIMENTAL
Intervention: Er:YAG laser deepithelization
Number of subjects: 12

Group type: COMPARATOR
Intervention: Scalpel deepithelization
Number of subjects: 12
Study: 12061947

Group type: EXPERIMENTAL
Intervention: Corticomotor threshold (CMT) in ALS patients with disease duration < 6 months (Group A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Corticomotor threshold (CMT) in ALS patients with disease duration > 24 months (Group B)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: M-wave amplitude in ALS patients (Group A and Group B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CMT correlation with disease duration
Number of subjects: 25
Study: 10192829

Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 mg/day
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/day
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 7798511

Group type: EXPERIMENTAL
Intervention: Bamiphylline (selective antagonist of A1 adenosine receptors)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bamiphylline
Number of subjects: 34
Study: 3674851

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (500 or 250 mg twice daily) for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxycillin (250 mg three times daily)
Number of subjects: 0
Study: 29090846

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg plus laser (COMBI)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Laser monotherapy (LASER)
Number of subjects: 128
Study: 26652026

Group type: EXPERIMENTAL
Intervention: MD2011001 cream
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44